期刊文献+

奥美沙坦酯中有关物质的HPLC测定 被引量:5

Determination of Related Substances in Olmesartan Medoxomil by HPLC
下载PDF
导出
摘要 建立了高效液相色谱法测定奥美沙坦酯中的有关物质。采用C18色谱柱,以30mmol/L磷酸二氢钾溶液(用磷酸调至pH3.5)-甲醇(40∶60)为流动相,检测波长256nm。在此条件下奥美沙坦酯与其合成中间体、降解产物分离情况较好。 An HPLC method was established for the determination of related substances in olmesartan medoxomil. A C18 column was used with the mobile phase of 30mmol/L monopotassium phosphate (adjusted to pH3.5 with phosphoric acid) -methanol (40 : 60) at the detection wavelength of 256nm.
作者 王桂云 马超
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2009年第3期205-206,共2页 Chinese Journal of Pharmaceuticals
关键词 奥美沙坦酯 有关物质 高效液相色谱 测定 olmesartan medoxomil related substance HPLC determination
  • 相关文献

参考文献4

  • 1徐彩丽,袁华,喻宗沅.奥美沙坦酯的研究进展[J].化学与生物工程,2005,22(4):7-8. 被引量:9
  • 2封宇飞,雷静,吕俊玲,刘志鹤,李金娥.新一代血管紧张素受体阻断剂奥美沙坦酯[J].中国新药杂志,2003,12(7):520-523. 被引量:23
  • 3Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide angiotensin Ⅱ receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole- 5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds [J]. JMed Chem, 1996, 39 (1) : 323-338.
  • 4柳泽宏明,藤本光一,雨宫由哉,等.1-联苯甲基咪唑衍生物的制备方法:中国,1189490[P].1998-08-05.

二级参考文献24

  • 1Neutel JM, Elliott WJ,Izzo JL, et al.Antihypertenslve efficacy of olmesartan medoxomil, a new angiotensin Ⅱ receptorantagonist, as assessed by ambulatory blood pressure measurements[J].J Clin Hypertens (Greenwich), 2002,4(5) : 325 - 331.
  • 2Uchler K, Laels P, Witte PU,et al .Antihypertensive efficacy of CS-866,a novel angiotensin-Ⅱ antagiotenist[abstraet no. 293].J Hypertension, 1997,15(Suppl 4) :S185.
  • 3Timmemans PB, Wong PC, Chiu AT, et al. Angiotensin Ⅱ receptors and angiotensin Ⅱ receptor antagonists[ J ]. Pharmacol Rev, 1993,45 (2) : 205.
  • 4BENICAR^TM tablets (olmesartan medoxomil).http://www.rxlist.com/cgi/generic/benicar _ cp. htm[EB/OL]. 2003 - 06 - 16.
  • 5Sehwocho LR, Masonson HN.Pharmacokinetics of CS-866, a new angiotensin Ⅱ receptor blocker, in healthy subjects[ J ].J Clin Pharmacol,2001,41(5) :515 - 527.
  • 6Kawaratani T, Puchler K, Laeis P, et al.Steady state pharmacokinetics of CS-866, a novel angqotensin Ⅱ receptor antagonist in elderly and young hypertensive patients[ abstract no. 9 ] [J]. J Hum Hypertens, 1999,13(Suppl 3) :S4.
  • 7Laeis P, Puchler K, yon Bergmann K.A comparative pharmacokinetic,safety and tolerability trail of the oral angiotensin Ⅱ antagonist olmesartan medoxomil in subjects with varying degrees of renal impairment and in health volunteers[abstract no.P2.147][J].J Hypertension,2001,19(Suppl 2):S145.
  • 8Bergmann K, Laeis P, Puchler K, et al. Olmesartan medoxornil:influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil[ J ]. J Hypertens,2001,19(Suppl1) :S33- S40.
  • 9Puchler K, Laeis P, Kawaratani T, et al. The effect of the combination,of the oral angiotensive Ⅱ-antagiotenist CS-866 and warfarin on pharmacodynamics, pharmacokinetics and safety in healthy, male subjects[abstract no.271][J].J Hypertension,1999,17(Suppl 3) : S275.
  • 10Laeis P,Puchler K,Kirch W.The effect of the oral angiotensive Ⅱ -antagiotenist Olmesartan medoxomil on the safety, tolerability and pharmacokinetics of digoxin in the healthy,male subjects[abstract no. 179] [J].J Hypertension ,2001,19(Suppl 2) :S154.

共引文献29

同被引文献54

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部